AAOS Releases Groundbreaking Annual Report on Sarcoma Care
Transforming the future of musculoskeletal oncology through comprehensive data analysis
The American Academy of Orthopaedic Surgeons' (AAOS) Musculoskeletal Tumor Registry (MsTR) has launched its inaugural Annual Report, representing a significant step forward in the field of musculoskeletal oncology. This report serves as the first nationwide compilation of real-world clinical data, meticulously gathered from physicians treating patients with complex bone and soft-tissue tumors.
Reflecting the dedication of health professionals across multiple institutions, the 2025 report collates 1,189 surgical procedures recorded between 2016 and 2025. Impressively, the dataset has seen a remarkable 67% growth, emphasizing the increasing volume of data submissions year on year. These insights are crucial for enhancing the quality of care for patients diagnosed with sarcomas.
Unlocking Insights for Better Treatment Strategies
Dr. Benjamin J. Miller, chair of the MsTR Steering Committee, highlights the significance of this inaugural report: "This marks a pivotal moment for musculoskeletal oncology. With high-quality, provider-entered data at our disposal for the first time, we can better understand treatment patterns and identify gaps within our practices that must be addressed to advance patient care."
The report provides an extensive overview of patient demographics, tumor characteristics, treatment modalities, and outcomes associated with bone and soft-tissue sarcoma care. By establishing standard measures across various institutions, orthopaedic surgeons and researchers can effectively monitor variations in clinical practice and evaluate device performance.
Key Highlights of the 2025 Annual Report
Demographics and Treatment Patterns
- The predominant age groups among patients are those aged between 60 to 79 years.
- Notably, limb salvage procedures accounted for 91.1% of all surgical interventions, demonstrating the prevalent approach in current sarcoma treatments.
Tumor and Treatment Characteristics
- The report reveals that soft-tissue sarcomas were more commonly documented than their bone sarcoma counterparts.
- Most tumors classified within the data were observed to be grade G3, indicating a critical aspect of tumor pathology that requires attention.
Improving Care Coordination
- Data showed that 68.9% of biopsies were conducted at the treating institution, with nearly one-third performed at referring entities. This presents an opportunity to simplify care pathways and enhance coordination among healthcare providers.
Insights into Device Usage
- The report demonstrates enhanced analytic methods capturing vital information regarding implant usage, enabling deeper dives into treatment effectiveness, device safety, and ongoing quality improvement initiatives.
Patient Outcomes After Surgical Interventions
- Encouragingly, almost 80% of patients were discharged either home or to a home-health facility post-surgery, underscoring successful surgical interventions.
Collaborative Efforts to Enhance Sarcoma Care
In partnership with the Musculoskeletal Tumor Society (MSTS), the MsTR aims to foster quality improvement and evidence-based decision-making in sarcoma management. The continued growth of participation in this registry will provide invaluable insights into treatment variability and the real-world effectiveness of care protocols. Such findings will ultimately assist the orthopaedic oncology community in delivering safer and more effective treatments for patients facing these challenging conditions.
About AAOS Registry Program
The mission of the AAOS Registry Program revolves around enhancing orthopaedic care through the accumulation, analysis, and reporting of significant clinical data. The flagship program, the American Joint Replacement Registry (AJRR), represents the largest national database of hip and knee joint replacement surgeries, encapsulating over 4.6 million procedures. Additional offerings of the registry program encompass several databases, promising continuous improvement in patient care through advanced analysis and knowledge sharing.
About the American Academy of Orthopaedic Surgeons
As the leading global association of musculoskeletal specialists, the American Academy of Orthopaedic Surgeons, with over 39,000 members, is committed to advancing the health of individuals through exceptional education and resources. AAOS is a trusted authority on musculoskeletal health, guiding improvements in patient treatment and ensuring that members stay at the forefront of orthopaedic practice.
Frequently Asked Questions
What is the Musculoskeletal Tumor Registry (MsTR)?
The MsTR is a national database collecting real-world clinical data to enhance care for sarcoma patients.
Why is the 2025 Annual Report significant?
This report is the first comprehensive analysis of national clinical data in musculoskeletal oncology, highlighting trends and treatment patterns.
What types of sarcomas are most commonly reported?
Soft-tissue sarcomas were more frequently reported than bone sarcomas according to the report.
How does the registry improve patient care?
The registry identifies treatment variations and provides insights that can lead to improved care pathways and outcomes.
What is the AAOS's role in sarcoma management?
AAOS provides education and resources that enhance the skills of orthopaedic surgeons to improve musculoskeletal health.
